WHI-P180

WHI-P180 is an inhibitor of RET and VEGFR2 used in studies of MAPK / ERK Signaling. In practice, this places the compound in experiments that measure mitogenic kinase cascades, proliferation control, and differentiation-linked signaling in angiogenesis, cancer, and cell signaling models.

By inhibiting RET and VEGFR2, WHI-P180 can be used to examine mitogenic kinase cascades, proliferation control, and differentiation-linked signaling. The kinase annotation adds relevance to biochemical kinase assays, phospho-signaling studies, and selectivity profiling, together with downstream-response mapping in the same experimental setting. In angiogenesis, cancer, and cell signaling models, these readouts can be combined with viability, reporter, localization, biochemical conversion, or morphology endpoints to refine experimental interpretation.

Research Applications

• Target-focused assays involving RET and VEGFR2
• Pathway perturbation studies connected to MAPK / ERK Signaling
• Concentration-response inhibition and target-dependence studies
• Biochemical kinase assays, phospho-signaling studies, and selectivity profiling

Overall, WHI-P180 is appropriate when a defined chemical perturbant is needed to connect RET and VEGFR2 with measurable biochemical, transcriptional, electrophysiological, imaging, or phenotypic readouts in angiogenesis, cancer, and cell signaling models. This profile is suited to mechanistic follow-up, comparative profiling, and assay optimization under defined exposure conditions.